




维亚王物科汉程版集团 VIVA BIOTECH HOLDINGS Stock Code: 1873.HK



#### Viva Biotech and Langhua Pharmaceutical Reached a Strategic Integration Agreement to Accelerate the Upgrade of the Innovative Drug Industry Service Chain

On August 8, 2020, Viva Biotech entered into the Share Purchase Agreement pursuant to which Viva Biotech agreed to acquire and the vendors agreed to collectively sell 80% of the equity interest in Langhua Pharmaceutical, at the consideration of RMB2,560 million. This strategic integration is of great strategic significance for Viva Biotech to establish a comprehensive one-stop drug service platform.



#### Viva Biotech and Synthesis Entered a Strategic Acquisition Agreement to Accelerate the Expansion of Global Innovative Drug R&D Service

On September 20, 2020, Viva Biotech entered into the agreement pursuant to which the Company agreed to acquire, and the vendor agreed to sell, the entire equity interest in SYNthesis med chem (Hong Kong) Limited, at the consideration of approximately US\$80 million, approximately HK\$620 million in total. This acquisition is of great strategic significance for Viva Biotech to vertically integrate the industry chain and establish a comprehensive one-stop drug service platform.



#### Viva BioInnovator (VBI) Successfully Held Demo Day 2

On September 10, 2020, Viva BioInnovator (VBI) successfully held the Demo Day 2 e-congress. Among nearly 60 incubation portfolio companies from the VBI platform, 5 startup companies attended this event, namely AmacaThera, XLEMENT, Path Therapeutics, Reglagene and VivaVision Biotech, covering numerous fields including pain, biochip detection, intractable epilepsy, eye diseases and cancer.





Over 200 domestic and overseas top-tier investors, representatives of investment institutions, R&D representatives of pharmaceutical companies, etc. participated in the event and conducted in-depth communication with company founders in an interactive way online.

#### Viva Biotech Joined Hands with Harbour BioMed to Establish a Strategic Partnership on Incubating Innovative Biotech Startups

On July 31, 2020, Viva Biotech announced a strategic partnership with Harbour BioMed, under which both parties will leverage their respective expertise in drug discovery and development to promote the incubation of innovative biotech startups. This complementary partnership will operate through EFS (equity for service) and scientific research model to create synergies on the technical level.

## HARBOUR BIOMED

#### Viva Biotech and Schrödinger Announced Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets



On July 28, 2020, Viva Biotech and Schrödinger, Inc. announced a strategic collaboration for the early development of new drugs. Both parties will leverage their respective expertise in drug discovery and development to enable discovery of first-in-class therapeutic candidates.

#### Viva Biotech Acquired Properties in Pudong District to Build New Headquarter in Shanghai

In July 2020, Viva Biotech successfully entered into a bid for a new property with a site area of approx. 40,000 sq.m., to build Viva Biotech Shanghai new headquarter in the future.



# Viva Biotech Linkedin

#### **Market Recognition**

#### QurAlis Was Recognized as the 'Fierce Biotech's 2020 Fierce 15'

On September 29, 2020, the well-known annual 'Fierce Biotech 2020 Fierce 15' list was released. QurAlis, a platform company incubated by Viva BioInnovator, was recognized as the 'Fierce Biotech 2020 Fierce 15'. As a biotech company focused on developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, QurAlis has been continuously committing to the development of new therapies for ALS and genetically related frontotemporal dementia (FTD).





#### **Business Progress**



#### Viva Biotech's Portfolio Company Dogma Therapeutics Reached the Acquisition Agreement with AstraZeneca on Dogma's Oral PCSK9 Inhibitor Program

On September 17, 2020, Dogma Therapeutics, a Viva Biotech Portfolio Company, reached an agreement for the acquisition of its oral PCSK9 program by AstraZeneca. Dogma Therapeutics will receive upfront as well as downstream payments linked to global regulatory and commercial milestones.

#### **Research & Development Progress**



# VivaVision Biotech's LFA1 Inhibitor VVN001 Submitted Application for Phase II Clinical Trial in US

On September 1, 2020, VivaVision Biotech, a leading ophthalmology novel drug developer, announced that the Company has submitted phase II clinical trial application to FDA for the new drug VVN001 for the treatment of xerophthalmia, and will initiate the clinical study in the fourth quarter of 2020.

### TechnoDerma Medicines's First-in-Class New Drug Is Expected to Solve the Hair Loss Problem for 700 Million People



In August 2020, TechnoDerma Medicines, which focused on the development of First-in-Class new drugs for skin-related diseases, announced that the Company's first hair growth project will apply for the US IND as the world's first innovative drug in the second half of this year and start phase I clinical trial. This project has successfully developed drug molecules with significant hair growth effects and global independent intellectual property rights.

#### **Investment Progress**



#### ABM Therapeutics Completed Series A+ Funding of USD\$20 Million

On August 7, 2020, ABM Therapeutics, a biomedical innovator focused on the research and development of small molecule drugs that can cross the blood brain barrier, announced the completion of USD\$20 million Series A+ funding. This round of funding will be used to accelerate the clinical research of ABM-1310 and the development of multiple existing preclinical projects.

About Viva Biotech

Listing Date 2019.05.09 Price (2020.10.16) HKD 8.38 52 WK Range HKD 3.67 – 10.46 Market Cap (2020.10.16) HKD 16.01B Viva Biotech's mission is to become a cradle for innovative biotechnology companies around the world. Viva Biotech has developed a scalable business model combing the conventional cash-for-service (CFS) model and its unique equity-for-service (EFS) model. Under the CFS model, the Group provides structure-based drug discovery services to its biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development, covering the full spectrum of the customers' needs for early stage drug discovery, including target protein expression and structure research, hit screening, lead optimization and drug candidate determination. Viva Biotech also provides drug discovery and incubation services to biotechnology start-up companies with high potential under its EFS model. As of June 30, 2020, Viva Biotech had provided drug discovery services to over 495 biotechnology and pharmaceutical customers worldwide, worked on over 1,300 independent drug targets, delivered over 17,000 protein complex structures and invested/ incubated a total of 56 early stage biotech start-ups.

Investor & Media Enquiries Viva Biotech Holdings website: www.vivabiotech.com.cn

For further information, please contact: Tel: 852-31506788 Email: ir@vivabiotech.com; VivaBiotech.hk@pordahavas.com